---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277988"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:54:52.350002+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme issues $1.5B in convertible notes; repurchases $1.02B of existing notes

## Summary
- Issued $750M 0% convertible notes due 2031 and $750M 0.875% notes due 2032; net proceeds ~$1.47B.
- Used ~$1.02B to repurchase 0.25% notes due 2027 and 1.00% notes due 2028 via private transactions.
- Entered capped call transactions ($182.7M) to limit dilution; cap price $136.78 vs conversion price $87.20.
- Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases.

## SEC filing metadata
- accession: 0001193125-25-277988
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277988
- JSON: https://secwatch.observer/filing/0001193125-25-277988.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277988.txt

## Key facts
- Debt Financings
  HALOZYME THERAPEUTICS, INC. incurred convertible notes of $1,500.0 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0% maturing due 2031.
  - Instrument: convertible notes
  - Principal: $1,500.0 million aggregate principal amount
  - Counterparty: The Bank of New York Mellon Trust Company, N.A.
  - Rate: 0%
  - Maturity: due 2031
  - Event: incurrence
  source text: completed its previously announced sale of $1,500.0 million aggregate principal amount convertible senior notes, consisting of (i) $750.0 million of 0% Convertible Senior Notes due 2031
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm
- Debt Financings
  HALOZYME THERAPEUTICS, INC. incurred convertible notes of $750.0 million in aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0.875% maturing due 2032.
  - Instrument: convertible notes
  - Principal: $750.0 million in aggregate principal amount
  - Counterparty: The Bank of New York Mellon Trust Company, N.A.
  - Rate: 0.875%
  - Maturity: due 2032
  - Event: incurrence
  source text: (ii) $750.0 million in aggregate principal amount of 0.875% Convertible Senior Notes due 2032
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.